PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 7, 2026Diagnostics0 citationsOpen Access

Comprehensive Genomic Profiling for Precision Oncology: Analytical Validation and Clinical Utility in Solid Tumors

View Full Paper
AMAshis K. MondalAVAshutosh VashishtVVVishakha Vashisht

Key Points

  • The research aims to validate the analytical and clinical performance of a CGP assay for solid tumors.
  • Evaluated a CGP assay for detecting genomic alteration types including SNVs, Indels, CNVs, and gene fusions.
  • Used 117 patient-derived FFPE tumor samples for validation.
  • Assessed assay performance via comparison with orthogonal methods and reproducibility evaluations.
  • Conducted limit-of-detection and tumor mutational burden (TMB) concordance analyses.
  • Achieved 100% sensitivity, specificity, and accuracy for variant detection.
  • Observed strong concordance for TMB estimation with R2 = 0.9925.
  • Confirmed accurate SNV detection at approximately 1% variant allele frequency.
  • Demonstrated robust reproducibility for both inter- and intra-run assays.

Abstract

Background: Comprehensive genomic profiling (CGP) is increasingly used in precision oncology to identify actionable genomic alterations and guide targeted therapies in solid tumors. However, the clinical implementation of CGP assays requires rigorous analytical validation to ensure accurate and reproducible detection of diverse genomic alterations across heterogeneous tumor samples. Despite rapid advancements in next-generation sequencing technologies, there remains a need for validated CGP platforms that demonstrate reliable performance and readiness for routine clinical use. Methods: This study evaluated the analytical and clinical performance of a CGP assay capable of detecting multiple genomic alteration types, including single nucleotide variants (SNVs), insertions/deletions (Indels), copy number variations (CNVs), gene fusions, and tumor mutational burden (TMB). Validation was conducted using patient-derived 117 FFPE tumor samples, external proficiency testing materials, and reference standards. Assay performance was assessed through comparison with orthogonal methods and through evaluation of reproducibility, limit of detection, and TMB concordance. Results: The assay demonstrated excellent analytical performance, achieving 100% sensitivity, specificity, and accuracy for variant detection across evaluated samples. Strong concordance was observed for TMB estimation (R2 = 0.9925), with consistent classification of TMB-high cases. The assay showed robust inter- and intra-run reproducibility and reliable detection of low-frequency variants. Limit-of-detection (LOD) analysis confirmed accurate SNV detection at approximately 1% variant allele frequency and reliable RNA fusion detection at low input levels. Conclusions: The validated CGP assay provides accurate, reproducible, and comprehensive detection of clinically relevant genomic alterations in solid tumors. These results support its suitability for routine clinical deployment, enabling reliable genomic profiling to inform precision oncology treatment decisions.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mondal et al. (2026) studied this question.

synapsesocial.com/papers/69d49fe5b33cc4c35a2284e0https://doi.org/10.3390/diagnostics16071087
Ask AI
Helpful
Bookmark
Share
View Full Paper